FindTrial
Sign In

The role of mTOR gene promoter polymorphism and methylation in the development of incomplete stent endothelialization and restenosis after implantation of sirolimus ramification-coated stent

The effect of mTOR gene promoter polymorphism and methylation on incomplete stent endothelialization and restenosis after implantation ofsirolimus ramification-coated stent

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039839
Enrollment
Unknown
Registered
2020-11-12
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Rapamycin stent implantation group:Rapamycin stent implantation

Sponsors

Zhoupu Hospital of New Pudong District in Shanghai City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years; 2. Diagnosis of unstable angina; 3. Stenosis of main coronary artery more than 70% and implantation of rapamycin coated stent; 4. Willing to participate in follow-up.

Exclusion criteria

Exclusion criteria: 1. Diagnosis of myocardial infarction with ST segment elevation within 1.3 months; 2. Pregnant women; 3. Severe hepatorenal insufficiency.

Design outcomes

Primary

MeasureTime frame
methylation level of rapamycin receptor gene promoter;—

Countries

China

Contacts

Public ContactSun Zhishan

Zhoupu Hospital of New Pudong District in Shanghai City

ningzhogping88@163.com+86 13637405536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026